The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy

Autor:	Xiaolin Liu, Jian-Bin Zhu, Ban-He Din, Yufeng Li, Ding-Shen Liu
Rok vydání:	2009
Předmět:	Adult Oncology Harringtonines Cancer Research medicine.medical_specialty Adolescent Newly diagnosed Imatinib therapy Piperazines Young Adult Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine Humans Medicine In patient Protein Kinase Inhibitors neoplasms business.industry Remission Induction Myeloid leukemia Imatinib Hematology Middle Aged Antineoplastic Agents Phytogenic Pyrimidines Drug Resistance Neoplasm Homoharringtonine Benzamides Immunology Imatinib Mesylate Drug Therapy Combination business medicine.drug
Zdroj:	Leukemia & Lymphoma. 50:1889-1891
ISSN:	1029-2403 1042-8194
DOI:	10.3109/10428190903216838
Popis:	Imatinib is the current standard first-line therapy for patients with newly diagnosed chronic myeloid leukemia (CML),but some of the patients will eventually develop resistance to imatinib therapy ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcee978dfc975769713f3192ce5f700f https://doi.org/10.3109/10428190903216838 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.